Comparative Pharmacology
Head-to-head clinical analysis: CLOCORTOLONE PIVALATE versus CORT DOME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOCORTOLONE PIVALATE versus CORT DOME.
CLOCORTOLONE PIVALATE vs CORT-DOME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clocortolone pivalate is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune responses, and inhibit phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Topical: Apply a thin film to affected area once or twice daily. Not for ophthalmic use. Maximum duration of 2 weeks per course.
Hydrocortisone (Cort-Dome) typical adult dose: 100 mg intravenously or intramuscularly as a loading dose, followed by 50-100 mg intravenously every 6 hours for stress dosing; for replacement therapy: oral 20-30 mg daily in divided doses. Topical: apply sparingly to affected area 1-4 times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5 hours (range 1-4 hours), reflecting rapid clearance; clinical duration exceeds half-life due to tissue binding.
Plasma half-life is approximately 1-2 hours; biological half-life (duration of adrenal suppression) is 18-36 hours.
Primarily renal (approximately 80%) as glucuronide and sulfate conjugates; minor biliary/fecal excretion (20%).
Primarily hepatic metabolism; renal excretion of inactive metabolites accounts for approximately 40-60% of elimination; less than 5% excreted unchanged in urine; biliary/fecal elimination is minor (<5%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid